Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions

Completed

Conditions: Breast Cancer

Interventions: Other: no intervention

First Posted Date: 2022-08-22

Last Posted Date: 2022-08-22

Lead Sponsor: Fudan University

Target Recruit Count: 1299

Registration Number: NCT05510037

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Application of ICG Fluorescence Cholangiography in Laparoscopic Living Donor Left Lateral Sectionectomy

Not Applicable

Completed

Conditions: Living Donor Liver Transplantation

Interventions: Procedure: indocyanine green (ICG) fluorescence cholangiography

First Posted Date: 2022-08-18

Last Posted Date: 2022-08-18

Lead Sponsor: Fudan University

Target Recruit Count: 85

Registration Number: NCT05506020

PD-1 Inhibitors With or Without Radiation in Advanced Melanoma

Phase 2

Not yet recruiting

Conditions: the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma

Interventions: Radiation: Radiation

First Posted Date: 2022-08-12

Last Posted Date: 2022-08-12

Lead Sponsor: Fudan University

Target Recruit Count: 92

Registration Number: NCT05498805

Locations: 🇨🇳
Fudan University Shanghai Cencer Center, Shanghai, Shanghai, China

Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation

Phase 2

Not yet recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Cisplatin
Radiation: EBRT
Radiation: VBT

First Posted Date: 2022-08-05

Last Posted Date: 2022-08-05

Lead Sponsor: Fudan University

Target Recruit Count: 294

Registration Number: NCT05489848

Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy

Phase 2

Recruiting

Conditions: Limited Stage Small Cell Lung Cancer

Interventions: Drug: Pamiparib

First Posted Date: 2022-08-02

Last Posted Date: 2022-08-02

Lead Sponsor: Fudan University

Target Recruit Count: 44

Registration Number: NCT05483543

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Neoadjuvant Radiation in Locally Advanced Breast Cancer

Phase 2

Recruiting

Conditions: Breast Neoplasms

Interventions: Radiation: Neoadjuvant radiotherapy

First Posted Date: 2022-07-29

Last Posted Date: 2022-07-29

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT05479409

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Acute and Chronic Pain After Video-assisted Thoracoscopic Surgery for Lung Cancer

Completed

Conditions: Lung Cancer

Interventions: Other: Hookwire localization

First Posted Date: 2022-07-28

Last Posted Date: 2022-10-24

Lead Sponsor: Fudan University

Target Recruit Count: 161

Registration Number: NCT05478460

Locations: 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer

Phase 1

Recruiting

Conditions: Cervical Cancer

Interventions: Biological: Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection

First Posted Date: 2022-07-27

Last Posted Date: 2022-07-28

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT05475847

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, No. 270, Dong'an Road, Xuhui District, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, No. 4333, Kangxin Road, Pudong New Area, Shanghai, Shanghai, China

MammaPrint Value for Pre-menopausal Breast Cancer Patients

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2022-07-26

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT05474391

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

Phase 2

Not yet recruiting

Conditions: Gastric Cancer
Adjuvant Therapy
PD-1 Immunotherapy
MSI-H

Interventions: Drug: SOX
Drug: PD-1 antibody
Other: Observation
Drug: XELOX

First Posted Date: 2022-07-21

Last Posted Date: 2022-08-26

Lead Sponsor: Fudan University

Target Recruit Count: 141

Registration Number: NCT05468138

Locations: 🇨🇳
Dazhi Xu, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy